Trending...
- Indies United is pleased to present our July 2025 book releases
- Bak Brothers, Inc. Expands Exterior Remodeling Services to La Grange, IL
- Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
NORTHBROOK, Ill.--(BUSINESS WIRE)--Endevica Bio, a company developing first-in-class peptide drug candidates with better safety and efficacy properties, announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) Application for its lead investigational product, TCMCB07, allowing the company to proceed with initiating clinical studies. TCMCB07 is an investigational melanocortin‐4 antagonist peptide designed to treat cachexia in people that have cancer and other chronic diseases. Endevica Bio plans to initiate Phase 2 clinical studies in pancreatic cancer in 2Q 2023.
"The acceptance of the IND means that Endevica begins its next chapter on our quest to improve the lives of people who are suffering from the effects of cachexia. We have been so encouraged by the pre-clinical data on TCMCB07 that have been generated to date and are looking forward to the next phase of its development," said Russ Potterfield, CEO and Executive Chairman of Endevica.
More on illi News
"People with cachexia are suffering as their bodies can't adequately process the nutrients they need to survive. The current standard of care, appetite stimulants and corticosteroids, are not adequate in effectively mitigating this condition," said Daniel Marks M.D., Ph.D., Chief Medical Officer of Endevica. "TCMCB07 has a lot of promise in its ability to modulate the body's behavioral and metabolic response to chronic illness, and we are hopeful that it will be proven to be a safe and effective treatment option."
"We designed TCMCB07 to be a first-in-class peptide drug. We are confident that its ability to cross the blood-brain barrier and act on previously inaccessible target receptors will be profoundly beneficial for patient outcomes. This is just the first product in our pipeline of next-generation peptide therapeutics," said Kenneth Gruber Ph.D., Chief Scientific Officer and Founder of Endevica.
With the IND in place, Endevica will be finalizing its Phase 2a protocol for a multi-national trial, which is expected to generate robust data about this potentially life-saving compound.
More on illi News
About Endevica Bio
Endevica Bio was formed to create first-in-class peptide drug candidates that form an entirely new class of therapeutics. Endevica's technology platform, protected by a family of patents and pending applications, allows for the modification of peptides to modulate activity of G-protein coupled receptors behind the blood-brain barrier. Endevica's initial drug candidate, TCMCB07, is designed to treat cancer cachexia, which is the cause of death for up to 40% of cancer patients. More information can be found at www.endevicabio.com.
Contacts
Endevica Bio
LeAnn Kuhlmann Qi
Chief Commercial Officer
(573) 881-5080
"The acceptance of the IND means that Endevica begins its next chapter on our quest to improve the lives of people who are suffering from the effects of cachexia. We have been so encouraged by the pre-clinical data on TCMCB07 that have been generated to date and are looking forward to the next phase of its development," said Russ Potterfield, CEO and Executive Chairman of Endevica.
More on illi News
- Real Estate Experts Highlight Jersey Shore as a Smart Buy in 2025
- Spur Chicago Announces "Mindfulness in eMOTION" Workshop
- Don't Get Left In The Dark: Duracell Urges Americans To Gear Up For A Stormier-Than-Average Season
- $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST
- West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care
"People with cachexia are suffering as their bodies can't adequately process the nutrients they need to survive. The current standard of care, appetite stimulants and corticosteroids, are not adequate in effectively mitigating this condition," said Daniel Marks M.D., Ph.D., Chief Medical Officer of Endevica. "TCMCB07 has a lot of promise in its ability to modulate the body's behavioral and metabolic response to chronic illness, and we are hopeful that it will be proven to be a safe and effective treatment option."
"We designed TCMCB07 to be a first-in-class peptide drug. We are confident that its ability to cross the blood-brain barrier and act on previously inaccessible target receptors will be profoundly beneficial for patient outcomes. This is just the first product in our pipeline of next-generation peptide therapeutics," said Kenneth Gruber Ph.D., Chief Scientific Officer and Founder of Endevica.
With the IND in place, Endevica will be finalizing its Phase 2a protocol for a multi-national trial, which is expected to generate robust data about this potentially life-saving compound.
More on illi News
- The AML Shop Launches New Financial Investigations Unit, Appoints Director to Lead the Initiative
- Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild
- New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
- The Herbal Care, Led by Markel Bababekov, Becomes a Top Dispensary in NYC's Upper East Side
- Digital Watchdog Launches New myDW Cloud Services
About Endevica Bio
Endevica Bio was formed to create first-in-class peptide drug candidates that form an entirely new class of therapeutics. Endevica's technology platform, protected by a family of patents and pending applications, allows for the modification of peptides to modulate activity of G-protein coupled receptors behind the blood-brain barrier. Endevica's initial drug candidate, TCMCB07, is designed to treat cancer cachexia, which is the cause of death for up to 40% of cancer patients. More information can be found at www.endevicabio.com.
Contacts
Endevica Bio
LeAnn Kuhlmann Qi
Chief Commercial Officer
(573) 881-5080
Filed Under: Business
0 Comments
Latest on illi News
- Tarp Supply Inc.® Prepares to Celebrate 21 Years of Excellence in the Tarps Industry
- Top Dentist Concord CA, Smile Makers Dental Care, Celebrates 500 5-Star Reviews
- Bio-Inspired Technology-Dynamic and Adaptable for unknown real-world environments
- ALIVE and KICKING: LAUGHTER NEVER GETS OLD has its World Premiere July 11-20 in St. Charles, IL
- AAR to announce fourth quarter fiscal year 2025 results on July 16, 2025
- Michael Reafsnyder opens solo exhibition at Scott Richards Contemporary Art in San Francisco
- Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
- New Dad Battles Leukemia and Wins!
- Kefir Comes to NASCAR as Lifeway Foods Races into Hometown Weekend with Driver Josh Bilicki at The Loop 110
- Recession-Proof Startups: What Business Plans Investors Are Actually Funding in 2025
- $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments
- $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
- City of Chicago Releases Annual Comprehensive Financial Report for Fiscal Year 2024
- Indies United is pleased to present our July 2025 book releases
- Endurance Warranty Earns 2025 Buyer's Choice Awards from ConsumerAffairs Through Verified Customer Reviews
- Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
- Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
- Naperville: Structure Fire in the 1600 Block of Country Lakes Drive
- Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
- Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings